SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
Sarah Cherian(ICMR-National Institute of Virology), NIC Team, Pragya D. Yadav, Varsha Potdar(ICMR-National Institute of Virology), Sujeet Kumar Singh(National Center for Disease Control), Samiran Panda(Indian Council of Medical Research), Priya Abraham(ICMR-National Institute of Virology), Mousumi Das(ICMR-National Institute of Virology), Santosh Jadhav(ICMR-National Institute of Virology), Nivedita Gupta(Indian Council of Medical Research), Partha Rakshit(National Center for Disease Control)
Cited by 658
Related Papers
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
|Nature|2021|1.4k
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
|The Lancet|2021|361
Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India
|bioRxiv (Cold Spring Harbor Laboratory)|2021|268
Prevalence of SARS-CoV-2 infection in India
|The Indian Journal of Medical Research|2020|225